Systematic Review of Therapy Used in Relapsed Or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
Authors:
Open Access
- 19 July 2018
- journal article
- review article
- Published by Taylor & Francis in Future Science OA
- Vol. 4 (7) , FSO322
Abstract
To identify real-world evidence on outcomes from therapies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), we systematically reviewed literature in Medline/Embase for DLBCL/FL-related articles on real-world results published during January 2012–May 2016. Among 33 included articles, therapies included stem cell transplant (SCT) and chemotherapy, including experimental regimens. The highest overall survival rates were observed for SCT, long considered an optimal strategy following initial relapse. Prognoses were inferior among DLBCL patients receiving rituximab-based regimens rather than SCT, particularly among studies that exclusively focused on those ineligible for SCT due to age or co-morbidity. A lack of viable treatment options for DLBCL/FL patients ineligible for SCT after relapse remains a significant gap in care. Lay abstract Non-Hodgkin lymphoma is the most prevalent blood cancer. Diffuse large B-cell lymphoma and follicular lymphoma account for nearly two-thirds of all non-Hodgkin lymphomas. One-third of patients with diffuse large B-cell lymphoma continue on to relapsed or refractory disease. While follicular lymphoma tends to be less aggressive, relapses do occur. Stem cell transplant and chemotherapy/immunotherapy are the current treatment options for relapsed or refractory patients. However, many patients are ineligible for stem cell transplant, due to age or preexisting medical conditions, so safe and effective treatment choices for these patients are a must. The lack of viable treatment options highlights this unmet need.Keywords
Funding Information
- R Huelin, M Stokes, Y Guo, M Hoog and T Bhagnani
This publication has 38 references indexed in Scilit:
- An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab eraBlood, 2014
- Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)Blood, 2013
- The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMTBone Marrow Transplantation, 2013
- High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B‐cell lymphoma in first relapse: results of the R‐NIMP GOELAMS studyBritish Journal of Haematology, 2013
- Watchful Waiting in Low–Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study DatabaseJournal of Clinical Oncology, 2012
- Allogeneic hematopoietic stem cell transplantation in patients with diffuse large B cell lymphoma relapsed after autologous stem cell transplantation: A GITMO studyAnnals of Hematology, 2012
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab EraJournal of Clinical Oncology, 2010
- Low Nonrelapse Mortality and Prolonged Long-Term Survival after Reduced-Intensity Allogeneic Stem Cell Transplantation for Relapsed or Refractory Diffuse Large B Cell Lymphoma: Report of the Société Française de Greffe de Moelle et de Thérapie CellulaireTransplantation and Cellular Therapy, 2010
- Favorable Long-Term Survival After Reduced-Intensity Allogeneic Transplantation for Multiple-Relapse Aggressive Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2009
- Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Relapsed, Refractory, and Transformed Indolent Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2008